Research ArticleGENETICS

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas

See allHide authors and affiliations

Science Advances  22 Apr 2020:
Vol. 6, no. 17, eaaz3221
DOI: 10.1126/sciadv.aaz3221

Article Information

vol. 6 no. 17

Online ISSN: 
History: 
  • Received for publication August 29, 2019
  • Accepted for publication January 21, 2020
  • .

Author Information

  1. Yuxiang Wang1,
  2. Aaron T. Wild2,3,
  3. Sevin Turcan4,
  4. Wei H. Wu1,
  5. Carlie Sigel5,
  6. David S. Klimstra5,
  7. Xiaoxiao Ma1,
  8. Yongxing Gong1,
  9. Eric C. Holland6,
  10. Jason T. Huse7 and
  11. Timothy A. Chan1,2,8,*
  1. 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  2. 2Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  3. 3Southeast Radiation Oncology, Charlotte, NC 28204, USA.
  4. 4Max-Eder Junior Group on Lower Grade Gliomas, Heidelberg University Hospital, Heidelberg, Germany.
  5. 5Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  6. 6Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC 98109, USA.
  7. 7Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  8. 8Immunogenomics and Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  1. *Corresponding author. Email: chant{at}mskcc.org

Altmetric

Article usage

Article usage: April 2020 to August 2020

AbstractFullPdf
Apr 20202763335625
May 202027768172
Jun 20203617235
Jul 20204837787
Aug 20200292

Stay Connected to Science Advances

Navigate This Article